Biohaven (NYSE:BHVN) Now Covered by Deutsche Bank Aktiengesellschaft

Stock analysts at Deutsche Bank Aktiengesellschaft began coverage on shares of Biohaven (NYSE:BHVN - Get Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat.com reports. The brokerage set a "buy" rating and a $65.00 price target on the stock. Deutsche Bank Aktiengesellschaft's target price points to a potential upside of 55.48% from the stock's current price.

BHVN has been the topic of a number of other reports. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Biohaven in a research note on Tuesday, December 17th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $61.00 price objective (up from $58.00) on shares of Biohaven in a research note on Wednesday, December 4th. TD Cowen raised their price objective on shares of Biohaven from $55.00 to $75.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $59.00 price objective on shares of Biohaven in a research note on Tuesday, December 17th. Fourteen analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $63.15.

Biohaven Trading Up 0.0 %

NYSE BHVN traded up $0.02 on Tuesday, hitting $41.81. 246,996 shares of the company were exchanged, compared to its average volume of 908,583. The company has a market cap of $4.23 billion, a PE ratio of -4.48 and a beta of 1.28. Biohaven has a 12 month low of $26.80 and a 12 month high of $62.21. The stock has a fifty day moving average of $38.63 and a 200-day moving average of $42.62.

Biohaven (NYSE:BHVN - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.67) by ($0.03). On average, analysts expect that Biohaven will post -8.9 earnings per share for the current year.

Insider Transactions at Biohaven

In other Biohaven news, Director John W. Childs bought 29,000 shares of Biohaven stock in a transaction dated Monday, December 30th. The stock was purchased at an average price of $35.94 per share, for a total transaction of $1,042,260.00. Following the completion of the purchase, the director now directly owns 2,368,741 shares of the company's stock, valued at approximately $85,132,551.54. This trade represents a 1.24 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 16.00% of the company's stock.

Hedge Funds Weigh In On Biohaven

Large investors have recently modified their holdings of the company. nVerses Capital LLC bought a new position in shares of Biohaven in the third quarter valued at approximately $50,000. Spire Wealth Management bought a new stake in Biohaven during the fourth quarter valued at approximately $56,000. Values First Advisors Inc. bought a new stake in Biohaven during the third quarter valued at approximately $78,000. US Bancorp DE lifted its position in Biohaven by 57.1% during the third quarter. US Bancorp DE now owns 2,173 shares of the company's stock valued at $109,000 after purchasing an additional 790 shares during the last quarter. Finally, KBC Group NV lifted its position in Biohaven by 24.5% during the third quarter. KBC Group NV now owns 2,250 shares of the company's stock valued at $112,000 after purchasing an additional 443 shares during the last quarter. 88.78% of the stock is currently owned by institutional investors.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.